JMCP Findings: Managed Care Approaches to Bispecific Antibodies

FINDINGS FROM THE AMCP MARKET INSIGHTS PROGRAM | October 2025

Bispecific antibodies (bsAbs) are a newer type of treatment for common blood cancers. Although they have benefits compared with other treatments, scientists and health care providers have questions about how and when to use them because they have less experience with them. This article describes important things about bsAbs for health care organizations to consider, like choosing the right medication for the right patient and making sure they are available to all patients who might need them.

To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025. Key insights from the discussion included that clinical efficacy is a primary consideration when evaluating the role of bsAbs in FL and DLBCL and that ongoing data collection is necessary for increased certainty in long-term outcomes, treatment comparisons, and real-world experience.

Read More

For more disease state research, view the Market Insights Program.